PTH(7-34), a commercially available antagonist peptide lacking the CBD, required a four-fold higher concentration of PTH antagonists (with CBD) to significantly reduce tumor burden in bone at weeks 3–5 (Figure 1A,B). This evidence concerns the gene PTH and neoplasm.